Skip to content
Dark
Search
Exclusive CEO Interviews
Home
Onyx Live
News
FDA Greenlit
Second Opinion
Exclusive Interviews
Press Releases
About Us
Read Onyx in other publications
Archive
April 2026
12:
Alexander Seyf, CEO, Autolomous | Onyx Live | Advanced Therapies 2026
April 2026
12:
Marinna Madrid, Co-Founder, Cellino | Onyx Live | JPM 2026
April 2026
6:
Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM)
April 2026
3:
FDA approvals - March 2026
April 2026
3:
Novartis to acquire Excellergy, adding Phase 1 anti-IgE program
April 2026
2:
Novo Nordisk's Awiqli delivers the first once-weekly basal insulin for type 2 diabetes
April 2026
2:
FDA approves Rocket's Kresladi as the first gene therapy for severe leukocyte adhesion deficiency-I
April 2026
2:
Aspect Biosystems Announces $280 Million Partnership with Government of Canada to Advance Development of Bioengineered Cellular Medicines
March 2026
31:
Brad Sitko, CIO, XOMA Royalty | Onyx Live | JPM 2026
March 2026
27:
Avi Veidman, CEO, Nucleai | Onyx Live | JPM 2026
March 2026
27:
Merck to Acquire Terns, Adding TERN-701 to Hematology Pipeline
March 2026
26:
Kali licenses KT501 to Sanofi in autoimmune disease deal
March 2026
26:
Denali’s AVLAYAH wins FDA accelerated approval in Hunter syndrome
March 2026
26:
FDA Clears Corcept’s Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
March 2026
25:
Will biotech still be relevant in 2030? | Treehill Partners Ep. 3 | JPM 2026
March 2026
25:
India semaglutide market sees new moves from Lupin, Zydus, and Sun Pharma
March 2026
24:
FDA expands IMCIVREE label to acquired hypothalamic obesity as EMANATE misses primary endpoints
March 2026
24:
Abbott completes Exact Sciences deal, expanding diagnostics portfolio in cancer screening
March 2026
24:
Paul Denslow, CEO, Intus Bio | Onyx Live | JPM 2026
March 2026
23:
Oryon Cell Therapies Reports Phase 1b/2a Data Showing Sustained Motor Improvements in People with Parkinson’s Disease
March 2026
23:
Oryon Cell Therapies Emerges From Stealth Focusing on Autologous Neuron Replacement Therapies for Parkinson’s Disease and Other Neurodegenerative Disorders
March 2026
22:
Mike Cordonnier, CEO, Carlsmed | Onyx Live | JPM 2026
March 2026
20:
Aldeyra receives FDA complete response letter for Reproxalap
March 2026
19:
Johnson & Johnson’s ICOTYDE brings a new oral IL-23 option to plaque psoriasis
March 2026
19:
FDA approves Alfasigma’s Lynavoy for primary biliary cholangitis
March 2026
19:
Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS
March 2026
18:
Novartis expands Cosentyx label with FDA approval in adolescent Hidradenitis Suppurativa
March 2026
17:
China approves commercial BCI system for cervical spinal cord injury patients
March 2026
17:
Lilly escalates compounding challenge after finding impurity in Tirzepatide-B12 products
March 2026
13:
Chris Hall, CEO, Personalis | Onyx Live | JPM 2026
March 2026
13:
Bristol Myers Squibb’s Mezigdomide Delivers Progression-Free Survival Benefit in Phase 3 SUCCESSOR-2 Trial
March 2026
13:
BioNTech sets leadership transition as Sahin and Türeci plan move to new mRNA company
March 2026
13:
Vertex posts positive week 36 phase 3 IgAN data for Povetacicept
March 2026
12:
Agilent Technologies targets pathology growth with $950 million Biocare Medical acquisition
March 2026
12:
FDA updates biosimilar development guidance as review experience accumulates
March 2026
11:
FDA approvals – February 2026
March 2026
10:
Xenon’s azetukalner meets Phase 3 endpoint in treatment-resistant focal onset seizures
March 2026
6:
Affinia cites low-dose engineered capsid strategy as AFTX-201 receives Fast Track
March 2026
5:
Twenty-seven years to one drug: How failure defined Cytokinetics before Aficamten
March 2026
4:
Slone Partners’ Leslie Loveless on the post-boom talent reset in biopharma
March 2026
4:
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
March 2026
4:
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)
February 2026
27:
A national prostate screening programme would do more than detect cancer
February 2026
27:
FDA greenlights Ascendis’ once-weekly YUVIWEL to boost growth in children with achondroplasia
February 2026
25:
FDA proposes “plausible mechanism” route for individualized ultra-rare disease drugs
February 2026
24:
Immedica Pharma’s Loargys adds an enzyme-replacement entrant for ultra-rare ARG1-D–related hyperargininemia
February 2026
23:
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
February 2026
21:
FDA approves Vanda’s Bysanti for schizophrenia and bipolar I manic or mixed episodes
February 2026
20:
A world-expert in Stargardt disease has developed a pill to slow vision loss: why Tinlarebant could win FDA approval
February 2026
19:
Moderna-FDA public dispute cools as Administration agrees to review amended mRNA flu vaccine application
February 2026
18:
Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM)
February 2026
18:
Verily launches free version of its Pre Exchange and Workbench solutions, powering precision health AI and discovery
February 2026
18:
Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors
February 2026
18:
Belite Bio concludes phase 3 Stargardt trials with nearly 40% retinal cell preservation
February 2026
17:
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
February 2026
15:
How India is leading a cancer revolution
February 2026
13:
Verily Pre is Now “Awardable” in DoW’s Tradewinds Solutions Marketplace
February 2026
12:
Key risk statements from boxed warning on six menopausal HRT labels removed by FDA
February 2026
12:
Acrotech Biopharma brings a new topical PDE4 option - Adquey - into a crowded eczema market.
February 2026
12:
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
February 2026
12:
Guardant publishes Phase III data on ctDNA detection of residual disease after colon cancer surgery
February 2026
12:
FDA approves Novocure’s Optune Pax for locally advanced pancreatic cancer
February 2026
11:
Cellares secures $257 million Series D to scale automated cell therapy manufacturing
February 2026
11:
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
February 2026
9:
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
February 2026
9:
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
February 2026
6:
IND accepted: Affinia advances gene therapy for BAG3 DCM with FDA
February 2026
6:
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
February 2026
5:
ImmunityBio begins Phase 2 evaluation of chemotherapy-free NK-cell combination in indolent lymphomas
February 2026
5:
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
February 2026
5:
SpyGlass Pharma Announces Pricing of Initial Public Offering
February 2026
5:
Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
February 2026
4:
Avidity details spin-off of precision cardiology assets as Novartis deal progresses
February 2026
4:
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 2026
4:
Affinia Therapeutics Announces FDA Acceptance of IND Application to Advance AFTX-201 to a Phase 1/2 Trial for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)
February 2026
3:
MassBio Applauds Passage of Appropriations Bill, $400 Million Increase in NIH Funding
February 2026
3:
Guardant Health to Participate in Upcoming Investor Conferences
February 2026
3:
Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies
February 2026
3:
Piramal Pharma Solutions commercializes tablet-in-capsule drug delivery capability
February 2026
3:
NYSE listing and China licensing deal signal AstraZeneca’s two-market strategy
February 2026
3:
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
February 2026
3:
Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients
February 2026
3:
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
February 2026
2:
FDA approvals - January 2026
February 2026
2:
Avidity Biosciences Announces Expected Record Date for Spin-Off
February 2026
2:
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
February 2026
2:
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions
February 2026
2:
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
February 2026
2:
Why Flatiron is betting on data quality, not hype, to power the next era of cancer care
January 2026
30:
“Efficacy with safety”: the north star behind Outpace’s next-gen engineered cell therapies
January 2026
29:
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
January 2026
29:
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
January 2026
29:
Lexicon Announces Proposed Public Offering of Common Stock
January 2026
29:
Opentrons Global Robotics Chief, James Atwood, Named Chief Executive Officer
January 2026
29:
From diagnostics to drug development: Scipher Medicine’s three-track strategy for high-impact immunology
January 2026
28:
Cellares Raises $257 Million Series D Led by BlackRock and Eclipse to Industrialize Global Cell Therapy Manufacturing with Breakthrough Automation
January 2026
28:
nChroma Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of Epigenetic Silencer CRMA-1001 for Chronic Hepatitis B
January 2026
28:
Why Novellia thinks the best biopharma data strategy starts with patients, not pipelines
January 2026
27:
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
January 2026
27:
Mark Lappe’s lean biotech model: smaller teams, bigger wins
